
[Federal Register Volume 82, Number 31 (Thursday, February 16, 2017)]
[Notices]
[Page 10909]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03144]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0001]


Pediatric Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of meeting of the Pediatric Advisory Committee. 
This meeting was announced in the Federal Register of January 5, 2017. 
The amendment is being made to reflect a change in the Center for Drug 
Evaluation and Research (CDER) products portion of the document. There 
are no other changes.

FOR FURTHER INFORMATION CONTACT: Marieann Brill, Office of the 
Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 32, Rm. 5154, Silver Spring, MD 20993, 240-402-3838, email: 
marieann.brill@fda.hhs.gov, or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call 
the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 5, 2017 
(82 FR 1345), FDA announced that a meeting of the Pediatric Advisory 
Committee (PAC) would be held on March 6 and 7, 2017. On page 1346, in 
the third column, the CDER products portion of the document is changed 
to read as follows:
    On March 6, 2017, the PAC will meet to discuss the following 
products (listed by FDA Center):

(1) Center for Drug Evaluation and Research (CDER)
    a. NITROPRESS (sodium nitroprusside)
    b. KUVAN (sapropterin dihydrochloride)

    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

    Dated: February 13, 2017.
Janice M. Soreth,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2017-03144 Filed 2-15-17; 8:45 am]
 BILLING CODE 4164-01-P


